Minoxidil topique 5 % face à Microneedling électrique + minoxidil 5 %
2 essais les comparent directement, sur les mêmes patients. Voir Minoxidil topique 5 % · Voir Microneedling électrique + minoxidil 5 %
Deux essais ajoutent au minoxidil topique 5 % des séances de microneedling électrique, à des rythmes différents. Chez 75 hommes chinois (Bao 2022, fiabilité limitée), une séance toutes les 3 semaines avec le minoxidil deux fois par jour fait gagner +56,45 cheveux épais par cm² en 24 semaines, contre +28,01 sous minoxidil seul, un écart très probablement réel ; pour l'épaississement du cheveu (+22,46 contre +18,7 µm), l'écart peut être dû au hasard. Chez 120 femmes non ménopausées (Liang 2022, fiabilité moyenne), une séance toutes les 2 semaines avec le minoxidil une fois par jour fait passer le nombre de cheveux de 99,68 à 130 par cm² en 24 semaines, contre de 101,37 à 111,32 sous minoxidil seul, un écart très probablement réel, et 95 % des femmes sont améliorées sur photos, contre 55,27 %. Les effets indésirables sont proches d'un groupe à l'autre.
Bao 2022
Essai randomisé, risque de biais élevé. Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.
| Critère | Minoxidil topique 5 % | Microneedling électrique + minoxidil 5 % | Écart |
|---|---|---|---|
| Gain de cheveux non-duvet depuis le départ | +28,01 cheveux par cm²Voir la citationTable 2. Changes in hair density after 24 weeks One-sample t test Hair count/cm2 Group 1 (n = Group 2 (n = Group 3 (n = 23) 23) 25) Non-vellus hair 28.01 ± 7.42 32.09 ± 4.51 56.45 ± 7.82 count P = 0.002 P = 0.004 P = 0.002 Vellus hair -13.74 ± 3.41 -10.56 ± 2.83 -16.67 ± 6.48 count P = 0.014 P = 0.064 P = 0.021 14.27 ± 3.24 21.53 ± 6.19 39.78 ± 7.79 Total hair count P = 0.046 P = 0.074 P < 0.001 of treatment P value One-way ANOVA Two-sample t test P value among the Group 1 vs Group 1 vs Group 2 vs three groups Group 2 Group 3 Group 3 t P < 0.001 P = 0.513 P < 0.001 P < 0.001 Bao L, Zong H, Fang S et al.. Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.. J Dermatolog Treat 2022, DOI 10.1080/09546634.2020.1770162. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | +56,45 cheveux par cm² toutes les 3 semaines, minoxidil deux fois par jourVoir la citationTable 2. Changes in hair density after 24 weeks One-sample t test Hair count/cm2 Group 1 (n = Group 2 (n = Group 3 (n = 23) 23) 25) Non-vellus hair 28.01 ± 7.42 32.09 ± 4.51 56.45 ± 7.82 count P = 0.002 P = 0.004 P = 0.002 Vellus hair -13.74 ± 3.41 -10.56 ± 2.83 -16.67 ± 6.48 count P = 0.014 P = 0.064 P = 0.021 14.27 ± 3.24 21.53 ± 6.19 39.78 ± 7.79 Total hair count P = 0.046 P = 0.074 P < 0.001 of treatment P value One-way ANOVA Two-sample t test P value among the Group 1 vs Group 1 vs Group 2 vs three groups Group 2 Group 3 Group 3 t P < 0.001 P = 0.513 P < 0.001 P < 0.001 Bao L, Zong H, Fang S et al.. Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.. J Dermatolog Treat 2022, DOI 10.1080/09546634.2020.1770162. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Très probablement réel |
| Gain de diamètre depuis le départ | +18,7 µmVoir la citationTable 3. Mean change in hair thickness from baseline to week 24 One-sample t test Group 1 (n = Group 2 (n = Group 3 (n = 23) 23) 25) Change in 18.70 ± 6.17 10.41 ± 4.83 22.46 ± 3.87 Non-vellus hair P < 0.001 P = 0.058 P < 0.001 thickness (μm) Data are presented as the mean ± standard deviation. One-way P value ANOVA Two-sample t test P value among Group 1 vs Group 1 vs Group 2 vs the three groups Group 2 Group 3 Group 3 t P = 0.002 P = 0.015 P = 0.259 P < 0.001 Bao L, Zong H, Fang S et al.. Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.. J Dermatolog Treat 2022, DOI 10.1080/09546634.2020.1770162. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | +22,46 µm toutes les 3 semaines, minoxidil deux fois par jourVoir la citationTable 3. Mean change in hair thickness from baseline to week 24 One-sample t test Group 1 (n = Group 2 (n = Group 3 (n = 23) 23) 25) Change in 18.70 ± 6.17 10.41 ± 4.83 22.46 ± 3.87 Non-vellus hair P < 0.001 P = 0.058 P < 0.001 thickness (μm) Data are presented as the mean ± standard deviation. One-way P value ANOVA Two-sample t test P value among Group 1 vs Group 1 vs Group 2 vs the three groups Group 2 Group 3 Group 3 t P = 0.002 P = 0.015 P = 0.259 P < 0.001 Bao L, Zong H, Fang S et al.. Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/β-catenin signaling pathway.. J Dermatolog Treat 2022, DOI 10.1080/09546634.2020.1770162. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle). | Peut être dû au hasard |
Liang 2022
Essai randomisé, risque de biais modéré. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.
| Critère | Minoxidil topique 5 % | Microneedling électrique + minoxidil 5 % | Écart |
|---|---|---|---|
| Densité capillaire totale | 101,37 → 102,47 cheveux par cm² 1 application par jourVoir la citationTABLE2|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 |Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 |P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 99,68 → 102,2 cheveux par cm² toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE2|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 |Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 |P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Peut être dû au hasard |
| Densité capillaire totale | 101,37 → 111,32 cheveux par cm² 1 application par jourVoir la citationTABLE2|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 |Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 |P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 99,68 → 130 cheveux par cm² toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE2|Dermoscopicassessmentduringthestudyperiodamongthethreegroups. Timepoint Mean±SD MX MX+SPT MX+MN Hairdensity(/cm2) Baseline 101.37±17.32 99.14±15.85 99.68±15.58 Week12 102.47±19.00 111.89±21.10 102.20±16.72 Week24 111.32±19.57 115.89±20.39 130.00±20.58 |Change 1.11±10.34 12.76±14.34 2.53±13.08 §Change 9.95±10.16 16.76±11.75 30.33±15.18 |P-value 0.514 <0.001 0.230 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Très probablement réel |
| Diamètre de la tige pilaire | 1 application par jourVoir la citationHairshaftdiameter(mm) Baseline 44.07±4.79 43.10±4.29 42.85±7.07 Week12 51.38±9.82 53.24±6.58 51.03±9.05 Week24 58.43±10.04 58.09±9.32 58.24±11.44 |Change 7.30±8.89 10.13±6.12 8.18±7.13 §Change 14.36±10.61 14.99±9.25 15.39±10.73 |P-value <0.001 <0.001 <0.001 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 – – – – – – – – – – – 0.597 – – – – – – – – 0.114 0.632 0.051 0.249 0.785 0.672 0.863 0.905 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | toutes les 2 semaines, minoxidil une fois par jourVoir la citationHairshaftdiameter(mm) Baseline 44.07±4.79 43.10±4.29 42.85±7.07 Week12 51.38±9.82 53.24±6.58 51.03±9.05 Week24 58.43±10.04 58.09±9.32 58.24±11.44 |Change 7.30±8.89 10.13±6.12 8.18±7.13 §Change 14.36±10.61 14.99±9.25 15.39±10.73 |P-value <0.001 <0.001 <0.001 §P-value <0.001 <0.001 <0.001 Citation complémentaire (significativite) PairwisecomparisonP-value ♯P-value MX MX MX+SPT vs. vs. Vs. MX+SPT MX+MN MX+MN – – – 0.824 – – – – – – – – <0.001 0.598 0.002 <0.001 0.009 <0.001 <0.001 <0.001 – – – – – – – – – – – 0.597 – – – – – – – – 0.114 0.632 0.051 0.249 0.785 0.672 0.863 0.905 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Peut être dû au hasard |
| Patients améliorés (panel photo en aveugle) | 55,27 % 1 application par jourVoir la citationAssessed by investigators according to global photographs, 55.27% of patients in the MX group, 86.49% of patients in the MX + SPT group, and 95.00% of patients in the MX + MN group showed improvement at week 24 (Figure4). Among the Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 95 % toutes les 2 semaines, minoxidil une fois par jourVoir la citationAssessed by investigators according to global photographs, 55.27% of patients in the MX group, 86.49% of patients in the MX + SPT group, and 95.00% of patients in the MX + MN group showed improvement at week 24 (Figure4). Among the Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Chute initiale sous minoxidil | 4 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 3 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Hyperkaliémie | 0 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 0 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Hypotension orthostatique | 1 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 1 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Incidence d'une pilosité accrue | 4 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 5 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Incidence de céphalées | 1 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 0 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Infection | 0 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 1 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Palpitations | 1 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 0 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Pellicules | 7 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 5 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Prurit | 8 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 9 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Troubles des règles | 0 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 0 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Urticaire | 1 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 0 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |
| Œdèmes des membres | 0 sur 38 1 application par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | 0 sur 40 toutes les 2 semaines, minoxidil une fois par jourVoir la citationTABLE5|Mainadverseeffectsduringthestudyperiodamongthethreegroups. MX MX+SPT MX+MN (n=38) (n=37) (n=40) Total 27 45 24 Facialhypertrichosis 4 5 5 Trichomadesisaggravating 4 4 3 Scalppruritus 8 8 9 Increasedscurf 7 6 5 Infection 0 0 1 Edemaofthelimbs 0 1 0 Headache 1 1 0 Palpitation 1 3 0 Posturalhypotension 1 0 1 Hyperkalemia 0 1 0 Menstrualdisorder 0 15 0 Urticaria 1 1 0 Liang X, Chang Y, Wu H et al.. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial.. Front Med (Lausanne) 2022, DOI 10.3389/fmed.2022.905140. Citation sous licence CC-BY. | Non testé |